Cellectar Biosciences to Present at the 37th Annual Roth Conference
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has announced its participation in the 37th Annual Roth Conference. The company's management team will deliver a corporate presentation on Monday, March 17, 2025, at 8:30 AM Eastern Time.
The presentation will provide an overview of the company and its operations. Interested parties can access the presentation through a webcast link, and a replay will be made available in the Events section of Cellectar's Investor Relations website.
Cellectar Biosciences (NASDAQ: CLRB), una società biopharmaceutica in fase avanzata specializzata nello sviluppo di farmaci per il trattamento del cancro, ha annunciato la sua partecipazione alla 37ª Conferenza Annuale Roth. Il team di gestione dell'azienda presenterà un intervento aziendale lunedì 17 marzo 2025, alle 8:30 ora orientale.
La presentazione fornirà una panoramica dell'azienda e delle sue operazioni. Le parti interessate possono accedere alla presentazione tramite un link al webcast e una registrazione sarà disponibile nella sezione Eventi del sito web delle Relazioni con gli Investitori di Cellectar.
Cellectar Biosciences (NASDAQ: CLRB), una compañía biofarmacéutica en etapa avanzada especializada en el desarrollo de medicamentos para el tratamiento del cáncer, ha anunciado su participación en la 37ª Conferencia Anual Roth. El equipo de gestión de la compañía realizará una presentación corporativa el lunes 17 de marzo de 2025, a las 8:30 AM hora del Este.
La presentación ofrecerá una visión general de la empresa y sus operaciones. Las partes interesadas pueden acceder a la presentación a través de un enlace de webcast, y se pondrá a disposición una repetición en la sección de Eventos del sitio web de Relaciones con Inversores de Cellectar.
Cellectar Biosciences (NASDAQ: CLRB)는 암 치료 약물 개발을 전문으로 하는 후기 단계의 임상 생명공학 회사로, 제37회 연례 로스 회의에 참여한다고 발표했습니다. 회사의 경영진은 2025년 3월 17일 월요일 오전 8시 30분 동부 표준시에 기업 발표를 진행할 예정입니다.
발표는 회사와 그 운영에 대한 개요를 제공할 것입니다. 관심 있는 분들은 웹캐스트 링크를 통해 발표에 접근할 수 있으며, Cellectar의 투자자 관계 웹사이트의 이벤트 섹션에서 재생이 제공될 예정입니다.
Cellectar Biosciences (NASDAQ: CLRB), une société biopharmaceutique en phase avancée spécialisée dans le développement de médicaments pour le traitement du cancer, a annoncé sa participation à la 37e Conférence Annuelle Roth. L'équipe de direction de l'entreprise présentera une présentation d'entreprise le lundi 17 mars 2025, à 8h30, heure de l'Est.
La présentation fournira un aperçu de l'entreprise et de ses opérations. Les parties intéressées peuvent accéder à la présentation via un lien de webdiffusion, et un enregistrement sera disponible dans la section Événements du site Web des Relations avec les Investisseurs de Cellectar.
Cellectar Biosciences (NASDAQ: CLRB), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Entwicklung von Krebsbehandlungsmedikamenten spezialisiert hat, hat seine Teilnahme an der 37. jährlichen Roth-Konferenz angekündigt. Das Management-Team des Unternehmens wird am Montag, den 17. März 2025, um 8:30 Uhr Eastern Time eine Unternehmenspräsentation halten.
Die Präsentation wird einen Überblick über das Unternehmen und seine Tätigkeiten geben. Interessierte Parteien können über einen Webcast-Link auf die Präsentation zugreifen, und eine Aufzeichnung wird im Bereich Veranstaltungen der Investor Relations-Website von Cellectar verfügbar sein.
- None.
- None.
FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows:
Date: Monday, March 17
Time: 8:30 AM Eastern Time
Webcast: Click HERE
A replay of the corporate presentation will be available on the Events section of the company’s Investor Relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
FAQ
When is Cellectar Biosciences (CLRB) presenting at the 2025 Roth Conference?
How can investors watch CLRB's Roth Conference presentation?
What will be discussed at CLRB's Roth Conference presentation?
What is Cellectar Biosciences' (CLRB) main business focus?
